MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET

Cancer Letters

Volumn 351, Issue 2, 2014, Pages 265-271

  Zhou, Jian Ya ^a   Chen, Xi ^a   Zhao, Jing ^a   Bao, Zhang ^a   Chen, Xing ^a   Zhang, Pei ^a   Liu, Zhen Feng ^a   Zhou, Jian Ying ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Gefitinib resistance; HGF; Lung cancer; MET; MiR 34a

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; GEFITINIB; MICRORNA 34A; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; HGF PROTEIN, HUMAN; MET PROTEIN, HUMAN; MICRORNA; MIRN34 MICRORNA, HUMAN; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; EGFR GENE; FEMALE; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; 3' UNTRANSLATED REGION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904765311     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.06.010     Document Type: Article

References (37)

1. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., Ohe Y., Yang J.J., Chewaskulyong B., Jiang H., Duffield E.L., Watkins C.L., Armour A.A., Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
2. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., Zhang S., Wang J., Zhou S., Ren S., Lu S., Zhang L., Hu C., Hu C., Luo Y., Chen L., Ye M., Huang J., Zhi X., Zhang Y., Xiu Q., Ma J., Zhang L., You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12:735-742.
3. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., Harada M., Yoshizawa H., Kinoshita I., Fujita Y., Okinaga S., Hirano H., Yoshimori K., Harada T., Ogura T., Ando M., Miyazawa H., Tanaka T., Saijo Y., Hagiwara K., Morita S., Nukiwa T., North-East Japan Study G. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
4. Han J.Y., Park K., Kim S.W., Lee D.H., Kim H.Y., Kim H.T., Ahn M.J., Yun T., Ahn J.S., Suh C., Lee J.S., Yoon S.J., Han J.H., Lee J.W., Jo S.J., Lee J.S. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J. Clin. Oncol. 2012, 30:1122-1128.
5. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
6. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
7. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., Ogino H., Kakiuchi S., Hanibuchi M., Nishioka Y., Uehara H., Mitsudomi T., Yatabe Y., Nakamura T., Sone S. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008, 68:9479-9487.
8. Bottaro D.P., Rubin J.S., Faletto D.L., Chan A.M., Kmiecik T.E., Vande Woude G.F., Aaronson S.A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251:802-804.
9. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol. 2003, 4:915-925.
10. Siegfried J.M., Weissfeld L.A., Singh-Kaw P., Weyant R.J., Testa J.R., Landreneau R.J. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res. 1997, 57:433-439.
11. Takanami I., Tanana F., Hashizume T., Kikuchi K., Yamamoto Y., Yamamoto T., Kodaira S. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 1996, 53:392-397.
12. Tsao M.S., Yang Y., Marcus A., Liu N., Mou L. Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. Hum. Pathol. 2001, 32:57-65.
13. Ichimura E., Maeshima A., Nakajima T., Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn. J. Cancer Res. 1996, 87:1063-1069.
14. Kasahara K., Arao T., Sakai K., Matsumoto K., Sakai A., Kimura H., Sone T., Horiike A., Nishio M., Ohira T., Ikeda N., Yamanaka T., Saijo N., Nishio K. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin. Cancer Res. 2010, 16:4616-4624.
15. Tanaka H., Kimura T., Kudoh S., Mitsuoka S., Watanabe T., Suzumura T., Tachibana K., Noguchi M., Yano S., Hirata K. Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs. Int. J. Cancer 2011, 129:1410-1416.
16. Yano S., Yamada T., Takeuchi S., Tachibana K., Minami Y., Yatabe Y., Mitsudomi T., Tanaka H., Kimura T., Kudoh S., Nokihara H., Ohe Y., Yokota J., Uramoto H., Yasumoto K., Kiura K., Higashiyama M., Oda M., Saito H., Yoshida J., Kondoh K., Noguchi M. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J. Thorac. Oncol. 2011, 6:2011-2017.
17. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
18. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
19. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat. Rev. Cancer 2012, 12:613-626.
20. Cao W., Yang W., Fan R., Li H., Jiang J., Geng M., Jin Y., Wu Y. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol. 2013.
21. Ichimura A., Ruike Y., Terasawa K., Shimizu K., Tsujimoto G. MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells. Mol. Pharmacol. 2010, 77:1016-1024.
22. Lal A., Thomas M.P., Altschuler G., Navarro F., O'Day E., Li X.L., Concepcion C., Han Y.C., Thiery J., Rajani D.K., Deutsch A., Hofmann O., Ventura A., Hide W., Lieberman J. Capture of microRNA-bound mRNAs identifies the tumour suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. 2011, 7:e1002363.
23. Chen X., Zhou J.Y., Zhao J., Chen J.J., Ma S.N., Zhou J.Y. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Anti-cancer Drugs 2013, 24:1039-1046.
24. Wang W., Li Q., Takeuchi S., Yamada T., Koizumi H., Nakamura T., Matsumoto K., Mukaida N., Nishioka Y., Sone S., Nakagawa T., Uenaka T., Yano S. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin. Cancer Res. 2012, 18:1663-1671.
25. Li Y., Guessous F., Zhang Y., Dipierro C., Kefas B., Johnson E., Marcinkiewicz L., Jiang J., Yang Y., Schmittgen T.D., Lopes B., Schiff D., Purow B., Abounader R. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009, 69:7569-7576.
26. Yang S., Li Y., Gao J., Zhang T., Li S., Luo A., Chen H., Ding F., Wang X., Liu Z. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene 2013, 32:4294-4303.
27. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., Patrawala L., Yan H., Jeter C., Honorio S., Wiggins J.F., Bader A.G., Fagin R., Brown D., Tang D.G. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17:211-215.
28. Wiggins J.F., Ruffino L., Kelnar K., Omotola M., Patrawala L., Brown D., Bader A.G. Development of a lung cancer therapeutic based on the tumour suppressor microRNA-34. Cancer Res. 2010, 70:5923-5930.
29. Lodygin D., Tarasov V., Epanchintsev A., Berking C., Knyazeva T., Korner H., Knyazev P., Diebold J., Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
30. Gallardo E., Navarro A., Vinolas N., Marrades R.M., Diaz T., Gel B., Quera A., Bandres E., Garcia-Foncillas J., Ramirez J., Monzo M. MiR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009, 30:1903-1909.
31. Tanaka N., Toyooka S., Soh J., Kubo T., Yamamoto H., Maki Y., Muraoka T., Shien K., Furukawa M., Ueno T., Asano H., Tsukuda K., Aoe K., Miyoshi S. Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer 2012, 76:32-38.
32. Kastl L., Brown I., Schofield A.C. MiRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res. Treat. 2012, 131:445-454.
33. Weeraratne S.D., Amani V., Neiss A., Teider N., Scott D.K., Pomeroy S.L., Cho Y.J. MiR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro. Oncol. 2011, 13:165-175.
34. Koizumi H., Yamada T., Takeuchi S., Nakagawa T., Kita K., Nakamura T., Matsumoto K., Suda K., Mitsudomi T., Yano S. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J. Thorac. Oncol. 2012, 7:1078-1085.
35. Yan D., Zhou X., Chen X., Hu D.N., Dong X.D., Wang J., Lu F., Tu L., Qu J. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest. Ophthalmol. Vis. Sci. 2009, 50:1559-1565.
36. Dang Y., Luo D., Rong M., Chen G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One 2013, 8:e61054.
37. Chen X., Zhou J.Y., Zhou J.Y. MicroRNA-34a: role in cancer and cardiovascular disease. Curr. Drug Targets 2014, 15:361-373.